EI
RARE icon

EAM Investors’s Ultragenyx Pharmaceutical RARE Stock Holding History

EAM Investors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,631
Closed -$3.26M – 336
2024
Q3 		$3.26M Buy
+58,631
New +$2.99M 0.49% 108
2021
Q1 		– Sell
-19,046
Closed -$2.64M – 424
2020
Q4 		$2.64M Buy
19,046
+1,858
+11% +$220K 0.43% 56
2020
Q3 		$1.41M Buy
+17,188
New +$1.42M 0.34% 123
2014
Q4 		– Sell
-26,186
Closed -$1.48M – 347
2014
Q3 		$1.48M Buy
+26,186
New +$1.32M 0.3% 139

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EAM Investors's RARE Position: Q4 2024 in Review

EAM Investors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 58,631 shares — an estimated $3.26M sold.

EAM Investors first reported a position in RARE in Q3 2014 and held it in 4 quarters. The position peaked at $3.26M in Q3 2024. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • EAM Investors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • EAM Investors sold 58,631 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $3.26M.
  • EAM Investors first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 4 quarters.
  • EAM Investors's Ultragenyx Pharmaceutical position peaked at $3.26M in Q3 2024.
  • 312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.